[{"id":"6c1bf2f9-a643-4b80-84fa-1e32b26a8869","acronym":"BTCRC-BRE18-337","url":"https://clinicaltrials.gov/study/NCT03911973","created_at":"2021-01-18T19:15:11.647Z","updated_at":"2024-07-02T16:34:37.336Z","phase":"Phase 1/2","brief_title":"Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers","source_id_and_acronym":"NCT03911973 - BTCRC-BRE18-337","lead_sponsor":"Kari Wisinski","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA1 negative","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • gedatolisib (PF-05212384)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 04/17/2019","start_date":" 04/17/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-07"},{"id":"bbbfc82f-903a-45d5-b69e-110239e6f06c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01445418","created_at":"2021-01-18T05:59:45.069Z","updated_at":"2024-07-02T16:36:54.336Z","phase":"Phase 1","brief_title":"AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer","source_id_and_acronym":"NCT01445418","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA mutation • BRCA1 negative","tags":["HER-2 • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA mutation • BRCA1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 05/12/2008","start_date":" 05/12/2008","primary_txt":" Primary completion: 09/02/2014","primary_completion_date":" 09/02/2014","study_txt":" Completion: 10/18/2019","study_completion_date":" 10/18/2019","last_update_posted":"2019-10-22"},{"id":"59c77bee-74da-4081-96e3-d3c6eaa72a3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02514499","created_at":"2021-01-18T12:09:00.478Z","updated_at":"2024-07-02T16:36:57.766Z","phase":"","brief_title":"Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study","source_id_and_acronym":"NCT02514499","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation • BRCA1 negative","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation • BRCA1 negative"],"overall_status":"Completed","enrollment":" Enrollment 350","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2019-07-24"}]